Bhageria Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

BHAGERIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹185.16

prior close

₹183.65

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-0.2% vs market

Dyes And Pigments peers, median of 8sector-2.3%+1.1% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 1.1 pts more than its Dyes And Pigments peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.7

15m

+0.5

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-1.0-0.2-2.3+1.1

Next day

+0.1-1.3+1.4-2.5+2.6

-3.3-3.1-0.3-4.6+1.2

-3.8-2.8-1.0-3.4-0.5

-2.5-2.5+0.0-3.6+1.0

-0.1-2.1+2.0-3.5+3.4

+2.1-0.2+2.2-1.0+3.1

15d

+10.0+1.0+9.0-1.0+11.0

+8.6+3.5+5.0+0.5+8.1

-5.9-1.9-3.9+0.7-6.6

-0.5+1.4-1.8+2.8-3.3

UpDownMarket · Nifty Microcap 250Sector · Dyes And Pigments peers, median of 8Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bhageria Industries reported strong FY25 results with standalone revenue from operations rising to Rs. 59,715.90 lakhs from Rs. 49,496.88 lakhs in FY24, a growth of about 20.6%. Standalone profit after tax more than doubled to Rs. 4,226.54 lakhs from Rs. 1,962.40 lakhs, with EPS at Rs. 9.68 vs Rs. 4.50. Consolidated PAT grew to Rs. 3,869.06 lakhs from Rs. 1,852.82 lakhs. The Chemical segment was the key growth driver, with segment profit jumping to Rs. 5,646.10 lakhs from Rs. 1,144.46 lakhs, though the Pharma segment widened its loss to Rs. 563.52 lakhs. The board recommended a dividend of Rs. 1.50 per share (30%) and appointed new Secretarial, Internal, and Cost Auditors. The statutory auditors issued an unmodified (clean) opinion.

Likely market impact

Strong double-digit revenue growth and over 100% jump in profits signal a robust year for shareholders, supported by a healthy dividend. The stock may see a positive reaction, though continued losses in the Pharma segment remain a point to watch.